NASDAQ:SCNX Scienture (SCNX) Stock Price, News & Analysis $0.40 +0.01 (+3.69%) As of 01:13 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Scienture Stock (NASDAQ:SCNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Scienture alerts:Sign Up Key Stats Today's Range$0.39▼$0.4250-Day Range$0.24▼$0.5152-Week Range$0.24▼$2.60Volume437,618 shsAverage Volume2.53 million shsMarket Capitalization$16.46 millionP/E RatioN/ADividend YieldN/APrice Target$1.50Consensus RatingHold Company Overview Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL. Read More Scienture Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreSCNX MarketRank™: Scienture scored higher than 60% of companies evaluated by MarketBeat, and ranked 343rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingScienture has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialScienture has a consensus price target of $1.50, representing about 268.6% upside from its current price of $0.41.Amount of Analyst CoverageScienture has only been the subject of 2 research reports in the past 90 days.Read more about Scienture's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Scienture is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scienture is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScienture has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Scienture's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.40% of the float of Scienture has been sold short.Short Interest Ratio / Days to CoverScienture has a short interest ratio ("days to cover") of 2.54, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scienture has recently decreased by 22.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScienture does not currently pay a dividend.Dividend GrowthScienture does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.19 News SentimentScienture has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Scienture this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for SCNX on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat Follows1 people have added Scienture to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scienture insiders have not sold or bought any company stock.Percentage Held by Insiders21.39% of the stock of Scienture is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.68% of the stock of Scienture is held by institutions.Read more about Scienture's insider trading history. Receive SCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scienture and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCNX Stock News HeadlinesSCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041May 6 at 8:05 AM | globenewswire.comScienture Holdings Secures $11.4 Million Structured Financing DealMay 1, 2026 | tipranks.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.May 6 at 1:00 AM | Profits Run (Ad)Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementApril 15, 2026 | markets.businessinsider.comScienture Holdings, Inc. Receives Additional 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price RequirementApril 15, 2026 | quiverquant.comQScienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year AheadApril 6, 2026 | theglobeandmail.comScienture Holdings, Inc. Reports 216% Revenue Growth and Significant Gross Margin Expansion in 2025March 30, 2026 | quiverquant.comQSCIENTURE Reports Year End 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comSee More Headlines SCNX Stock Analysis - Frequently Asked Questions How have SCNX shares performed this year? Scienture's stock was trading at $0.51 at the start of the year. Since then, SCNX shares have decreased by 20.2% and is now trading at $0.4070. How were Scienture's earnings last quarter? Scienture Holdings, Inc. (NASDAQ:SCNX) posted its quarterly earnings results on Monday, March, 30th. The company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $1.48. The firm earned ($0.17) million during the quarter, compared to analyst estimates of $0.49 million. How do I buy shares of Scienture? Shares of SCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scienture own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scienture investors own include Cogent Communications (CCOI), Cavco Industries (CVCO), Liberty Broadband (LBRDK), Liberty Global (LBTYB), PayPal (PYPL), Roku (ROKU) and Arch Capital Group (ACGL). Company Calendar Last Earnings3/30/2026Today5/06/2026Next Earnings (Estimated)5/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SCNX's financial health is in the Yellow zone, according to TradeSmith. SCNX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryWholesale Current SymbolNASDAQ:SCNX Previous SymbolNASDAQ:MEDS CIK1382574 Webwww.trxadehealth.com Phone(800) 261-0281Fax800-265-6932EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Scienture$1.50 High Price Target$1.50 Low Price Target$1.50 Potential Upside/Downside+268.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.51 million Net MarginsN/A Pretax Margin-10,071.06% Return on Equity-53.25% Return on Assets-41.55% Debt Debt-to-Equity RatioN/A Current Ratio2.89 Quick Ratio2.82 Sales & Book Value Annual Sales$430 thousand Price / Sales38.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book0.24Miscellaneous Outstanding Shares40,630,000Free Float31,940,000Market Cap$16.54 million OptionableN/A Beta3.32 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:SCNX) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredTrump and Elon are BACK15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...InvestorPlace | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredWhere the SpaceX "Tidal Wave" hits firstThe SpaceX and xAI IPO could trigger one of the largest capital shifts in market history — $1.75 trillion movi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scienture Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scienture With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.